These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 18221241)
1. The evolution of pharmacological treatment for Parkinson's disease. Almeida QJ; Hyson HC Recent Pat CNS Drug Discov; 2008 Jan; 3(1):50-4. PubMed ID: 18221241 [TBL] [Abstract][Full Text] [Related]
2. Recent developments in the pharmacological treatment of Parkinson's disease. Tuite P; Riss J Expert Opin Investig Drugs; 2003 Aug; 12(8):1335-52. PubMed ID: 12882620 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications. Stowe R; Ives N; Clarke CE; Deane K; ; Wheatley K; Gray R; Handley K; Furmston A Cochrane Database Syst Rev; 2010 Jul; (7):CD007166. PubMed ID: 20614454 [TBL] [Abstract][Full Text] [Related]
4. Current pharmacotherapeutic treatment options in Parkinson's disease. Rezak M Dis Mon; 2007 Apr; 53(4):214-22. PubMed ID: 17586328 [TBL] [Abstract][Full Text] [Related]
5. Treatment Strategies in Early Parkinson's Disease. Marsili L; Marconi R; Colosimo C Int Rev Neurobiol; 2017; 132():345-360. PubMed ID: 28554414 [TBL] [Abstract][Full Text] [Related]
6. Parkinson's disease--levodopa complications. King DB Can J Neurol Sci; 1999 Aug; 26 Suppl 2():S13-20. PubMed ID: 10451755 [TBL] [Abstract][Full Text] [Related]
7. Off spells and dyskinesias: pharmacologic management of motor complications. Khan TS Cleve Clin J Med; 2012 Jul; 79 Suppl 2():S8-13. PubMed ID: 22761271 [TBL] [Abstract][Full Text] [Related]
9. Treatment of levodopa-induced motor complications. Stocchi F; Tagliati M; Olanow CW Mov Disord; 2008; 23 Suppl 3():S599-612. PubMed ID: 18781681 [TBL] [Abstract][Full Text] [Related]
10. Alternatives to levodopa in the initial treatment of early Parkinson's disease. Lees A Drugs Aging; 2005; 22(9):731-40. PubMed ID: 16156677 [TBL] [Abstract][Full Text] [Related]
11. Levodopa-related wearing-off in Parkinson's disease: identification and management. Pahwa R; Lyons KE Curr Med Res Opin; 2009 Apr; 25(4):841-9. PubMed ID: 19228103 [TBL] [Abstract][Full Text] [Related]
12. Other pharmacological treatments for motor complications and dyskinesias. Waters C Mov Disord; 2005; 20 Suppl 11():S38-44. PubMed ID: 15822104 [TBL] [Abstract][Full Text] [Related]
13. Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's disease. Petzer JP; Castagnoli N; Schwarzschild MA; Chen JF; Van der Schyf CJ Neurotherapeutics; 2009 Jan; 6(1):141-51. PubMed ID: 19110205 [TBL] [Abstract][Full Text] [Related]
14. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial. ; Gray R; Ives N; Rick C; Patel S; Gray A; Jenkinson C; McIntosh E; Wheatley K; Williams A; Clarke CE Lancet; 2014 Sep; 384(9949):1196-205. PubMed ID: 24928805 [TBL] [Abstract][Full Text] [Related]
15. Current and experimental treatments of Parkinson disease: A guide for neuroscientists. Oertel W; Schulz JB J Neurochem; 2016 Oct; 139 Suppl 1():325-337. PubMed ID: 27577098 [TBL] [Abstract][Full Text] [Related]
16. Community and long-term care management of Parkinson's disease in the elderly: focus on monoamine oxidase type B inhibitors. Chen JJ; Fernandez HH Drugs Aging; 2007; 24(8):663-80. PubMed ID: 17702535 [TBL] [Abstract][Full Text] [Related]
17. Understanding Parkinson's disease: an update on current diagnostic and treatment strategies. Pahwa R J Am Med Dir Assoc; 2006 Sep; 7(7 Suppl 2):4-10. PubMed ID: 17948613 [TBL] [Abstract][Full Text] [Related]
18. Can we achieve neuroprotection with currently available anti-parkinsonian interventions? Olanow CW Neurology; 2009 Feb; 72(7 Suppl):S59-64. PubMed ID: 19221316 [TBL] [Abstract][Full Text] [Related]
19. Drug selection and timing of initiation of treatment in early Parkinson's disease. Schapira AH; Olanow CW Ann Neurol; 2008 Dec; 64 Suppl 2():S47-55. PubMed ID: 19127579 [TBL] [Abstract][Full Text] [Related]
20. Early pharmacologic treatment in Parkinson's disease. Hauser RA Am J Manag Care; 2010 Mar; 16 Suppl Implications():S100-7. PubMed ID: 20297870 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]